Our results demonstrate that GLP-1 receptor agonists provide better cardiovascular protection than SGLT2 inhibitors in patients with HFpEF and DM, significantly reducing the risk of cardiovascular events, progression to SHF, and stroke. Here, SLC5A2 is linked to diabetes mellitus.